In conclusion, this study provided prospective paired tumor tissue and plasma samples, allowing for a more comprehensive and accurate analysis of GPS at the first-line treatment failure of osimertinib for EGFR-mutant locally advanced or metastatic NSCLC patients. This evidence concerns the gene EGFR and neoplasm.